<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942109</url>
  </required_header>
  <id_info>
    <org_study_id>TORNADO KB/202/2013</org_study_id>
    <nct_id>NCT01942109</nct_id>
  </id_info>
  <brief_title>The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure</brief_title>
  <acronym>TORNADO</acronym>
  <official_title>The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the effects of torasemide and furosemide on clinical and
      biochemical parameters of hemodynamic and neurohormonal compensation and myocardial
      remodeling in patients with chronic heart failure with indications for use of loop diuretics.

      The study protocol 100 patients with heart failure NYHA (New York Heart Association) II-IV
      (stable or exacerbation aligned cardiopulmonary at the time of enrollment, with a fixed-dose
      loop diuretics]) treated with optimal medical therapy as clinically indicated for use loop
      diuretics. Patients will be randomized to treatment with furosemide and torasemide
      (randomization 1 : 1). After randomization, furosemide will continue in its current
      fixed-dose or will be replaced by equipotential dose of torasemide (4:1). The minimal
      follow-up of patients in the study will be at least six months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to current guidelines, angiotensin converting enzyme inhibitors and
      beta-adrenolytics are the first-line treatment agents in patients with heart failure. In case
      of fluid retention, diuretics, as a part of symptomatic treatment, should be administered. In
      practice, the most common diuretic used in patients with heart failure is loop diuretic -
      furosemide. What is important, furosemide has no effect on patients' outcomes. Some studies
      showed unfavourable influence of this drug on rennin-angiotensin-aldosterone system.

      Alternative loop diuretic, which may be administered in patients with heart failure is
      torasemide. Its longer elimination half-life time, similar diuretic effects, lower influence
      on electrolyte disorders and additional pleiotropic effects could make torasemide more
      beneficial than furosemide.

      Accordingly, only direct comparison of furosemide and torasemide could present similarities
      and differences of these two agents.

      The hypothesis of this study is that torasemide may present more favourable effects on some
      clinical parameters in patients with heart failure, than furosemide (e.g. clinical symptoms,
      biochemical parameters, activity of rennin-angiotensin-aldosterone system, side effects).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The influence of therapy on cardiovascular events associated with heart failure (deaths, hospitalisations)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of dosing of diuretic due to worsening of condition of patient.</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of NYHA (New York Heart Association) class - worsening or improvement</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The measurement of fluid retention with ZOE Fluid Status Monitor</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>≥30% or ≥200 pg/ml increase of NTproBNP (N-terminal pro B type natriuretic peptide) level compared with baseline value</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change between baseline and final levels of serum biomarkers</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The assessment of quality of life</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive furosemide as a diuretic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Torasemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive torasemide as a diuretic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide</description>
    <arm_group_label>Furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torasemide</intervention_name>
    <description>Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide</description>
    <arm_group_label>Torasemide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  heart failure NYHA II-IV

          -  previous treatment with diuretics

          -  age&gt;18 years

        Exclusion Criteria:

          -  uncontrolled hypertension

          -  uncontrolled diabetes

          -  creatinine &gt; 2,5 mg/dl

          -  potassium &gt; 6 mg/dl

          -  acute coronary syndrome

          -  hypertrophic cardiomyopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcin Grabowski, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>1st Department of Cardiology Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcin Grabowski, PhD</last_name>
    <phone>+48 660 751 816</phone>
    <email>marcin.grabowski@wum.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paweł Balsam, PhD</last_name>
    <phone>+48 605152120</phone>
    <email>pawel.balsam@me.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>3rd Clinic of Internal Medicine and Cardiology of Medcial University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-382</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrzej Folga, PhD</last_name>
      <phone>+48 509 935 844</phone>
      <email>and.folga@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrzej Folga, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Artur Mamcarz, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcin Wełnicki</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Śliż, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>1st Department of Cariology of Medcial University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Grabowski, PhD</last_name>
      <phone>+48 660 751 816</phone>
      <email>marcin.grabowski@wum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Marcin Grabowski, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grzegorz Opolski, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paweł Balsam, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renata Główczyńska, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eliza Kozyra-Pydys, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krzysztof J Filipiak, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michał Peller, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Marcin Grabowski</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>diuretics</keyword>
  <keyword>furosemide</keyword>
  <keyword>torasemide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Torsemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

